You’re thinking about exactly the right trade‑off; you’re not “wrong,” but the way you’re framing it is a bit too binary. The best strategy now is a  **hybrid** : stay within the 6 categories for this hackathon, but broaden the drug list *within them* in a smart, tiered way instead of trying to “cover everything” or staying frozen at 30.

Let’s unpack it.

---

## Are 6 categories enough?

Your 6 categories — Pain, Antibiotics, Diabetes, Cardiovascular, Gastric, Respiratory — map very closely to the dominant problems in Indian OPD and to the largest therapeutic blocks in NLEM (anti‑infectives, cardiovascular, gastrointestinal, endocrine, respiratory).[pmc.ncbi.nlm.nih**+1**](https://pmc.ncbi.nlm.nih.gov/articles/PMC10357919/)

That means:

* You’re already aligned with **priority health needs** and essential medicines logic in India.[main.icmr.nic**+1**](https://main.icmr.nic.in/sites/default/files/upload_documents/Report_and_NLEM_2022.pdf)
* Judges won’t penalise you for “only 6” if those 6 clearly cover the bulk of real‑world cases (fever/infection, diabetes, hypertension/lipids, asthma/COPD, GERD).

So: keeping 6 categories is **fine and defensible** for this competition.

---

## Is expanding drug count *within* those 6 “bad”?

Your worry is: “We already have drugs that treat these categories; why add more?” That underestimates how doctors actually prescribe:

* They don’t want *one* antibiotic, *one* NSAID, *one* statin; they want **choice within the class** based on renal function, pregnancy, interactions, cost, etc.[ijpsr**+1**](https://ijpsr.com/bft-article/indias-national-list-of-essential-medicines-2022-a-descriptive-analysis/)
* NLEM itself lists **multiple** agents per class to allow for such nuance.[pmc.ncbi.nlm.nih**+1**](https://pmc.ncbi.nlm.nih.gov/articles/PMC10357919/)

So adding more drugs *inside* those 6 categories is **not redundant** if you do it like this:

* Tier 1 (broad): 80–120 drugs with basic, verified coverage (indication, pricing, reimbursement).
* Tier 2 (deep): 30–40 “hero” drugs (your current set plus a few) with rich interactions, comparisons, HCP write‑ups.

That way, when a judge or HCP tries a somewhat different antibiotic/statin/PPI, you don’t look blind; you just sometimes give a simpler answer on the Tier‑1 drugs.

---

## What about adding totally new categories now?

Expanding to psychiatry, rheumatology, oncology, etc. would **definitely** be heavy:

* Each new area needs more careful interactions and comorbidity reasoning (e.g., psych + cardiac QT risk, oncology + neutropenia) to not look shallow or unsafe.[pmc.ncbi.nlm.nih**+1**](https://pmc.ncbi.nlm.nih.gov/articles/PMC10305940/)
* You’d need new comparison tables, new interaction scenarios, and new reimbursement nuances (e.g., chemo under PM‑JAY) — that’s a lot of work in limited time.

Given the time and the fact that other teams are “suffering to collect data,” going broad into many new categories now is  **likely a trap** : you’ll spread thin, and your differentiator (India‑specific depth in a focused space) will blur.

---

## So what’s the right move now?

1. **Keep the 6 categories for this hackathon.**

   They already align with major primary‑care and chronic disease burdens: infections, pain, diabetes, hypertension/lipids, asthma/COPD, GERD.[pmc.ncbi.nlm.nih**+1**](https://pmc.ncbi.nlm.nih.gov/articles/PMC12506212/)
2. **Increase drug breadth *inside* those 6 in a tiered way.**

   * Use official sources (Jan Aushadhi, NLEM, CGHS/ESIC lists) to add maybe **50–80 more generics** in these same categories.[thehealthmaster**+2**](https://thehealthmaster.com/wp-content/uploads/2023/01/Jan-Aushadhi-Medicine-list-2023.pdf)
   * For each new drug: ensure at least name, strength, Jan Aushadhi price, and scheme coverage are correct.
   * Mark them `verification_level = "basic"` vs your existing `verification_level = "deep"` for the original 30–40.
3. **Double down on depth + safety in your current 30–40 “deep” drugs.**

   * This is where interactions, comparisons, and India‑specific reimbursement logic shine.
   * Build your demo and pitch mostly around these, while being able to show that “the system already knows many more molecules at a basic level.”
4. **Sell it as a pipeline, not a fixed list.**
   In Q&A, you then say:

   * “We’ve implemented a pipeline that ingests new generics from Jan Aushadhi and CGHS / NLEM with verified pricing and formulary status. Today we have deep clinical intelligence for ~30–40 high‑volume molecules and basic coverage for ~X more within the same 6 priority categories. Extending to new classes is now a data ingestion exercise, not a redesign.”

That’s a much stronger story than either extreme (“only 30 drugs” or “we tried to cover everything and did nothing deeply”).

So your instinct that **going wide across many new categories is risky right now** is correct, but the conclusion “then we shouldn’t expand drugs within the 6” is too conservative. The sweet spot is: **stay in 6 categories, expand drug breadth intelligently, and keep depth where it matters most.**
